Go to the profile of William Frey II

William Frey II

Director Alzheimer's Research Center & Pharmaceutical Consultant, Pharmaceutical and Biotechnology Industry

Noninvasive intranasal stem cells bypass the blood-brain barrier to target the brain to treat Parkinson's disease, stroke, MS, brain tumors, cerebral ischemia, Alzheimer's and other CNS disorders.

Regenerative medicine and therapeutic cell treatment of disorders of the brain and spinal cord are hindered by the blood-brain barrier. Invasive implantation of therapeutic cells in the brain, including stem cells and immune cells, is both risky and impractical. Noninvasive intranasal cell delivery to the CNS provides a solution to this problem.
Go to the profile of William Frey II
Dec 17, 2014